CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Research: Informed Container Choices Reduce Risk and Cost for Temperature-Sensitive Pharmaceutical Shipments

Peli BioThermal white paper addresses active and passive container options and provides selection guidance
Peli BioThermal, the global name in temperature controlled packaging, recently released a white paper addressing market solutions for protecting  temperature-sensitive pharmaceuticals while in transit. The white paper, titled “Active Shipping Containers vs Passive Shipping Containers,” provides guidance on making the optimum choice to eliminate confusion, reduce risk and save money evaluating the two main classes of containers used to ship temperature-sensitive pharmaceutical products.
“When it comes to maintaining the clinical efficacy of pharmaceuticals, one of the most important criteria is often temperature,” said Kevin Lawler, VP of sales at Peli BioThermal and contributor to the new white paper. “While there are many cold chain container options out there, making the best choice — one that reduces risk and is most cost-effective — involves assessing a variety of factors. And, these factors can vary payload to payload. There’s not a one-size-fits all solution.”
Given the highly competitive nature of the cold chain sector that has evolved to meet the needs of temperature-sensitive pharmaceuticals, there are many different positions regarding the best ways to address this physically complex issue. This white paper presents an overview of both active and passive containers and provides guidance for the selection of the most appropriate solution for a given payload.
Topics addressed in the white paper include:

  • The need for pharma temperature monitoring, including regulatory compliance, cold chain route qualification and temperature profiling
  • Benefits and drawbacks to both active and passive containers
  • What it means to ‘pre-qualify’ containers
  • Advanced passive packaging system options and how to evaluate the differences between solutions
  • Additional considerations for selecting the optimum temperature-controlled packaging, including modeling, single-use vs reusable shippers and environmental considerations

In addition to the team at Peli BioThermal, experts referenced in the white paper include representatives from PWC, Dickson Inc. and World Courier.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026